LIVE
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%

Molbio Diagnostics IPO: ₹930 Cr Issue Opens Aug 10

By ThePip DeskMolbio Diagnostics IPO: ₹930 Cr Issue Opens Aug 10

Molbio Diagnostics IPO launches Aug 10-12, priced at ₹768-807. The ₹930.7 Cr issue includes a ₹200 Cr fresh component for R&D and expansion.

Molbio Diagnostics, the Goa-based firm behind the Truenat rapid disease testing platform, will launch its Initial Public Offering (IPO) on August 10. The ₹930.7 crore offering includes a fresh issue of ₹200 crore and an offer for sale by existing shareholders.

  • Total IPO Size: ₹930.7 crore
  • Fresh Issue Component: ₹200 crore
  • Share Price Band: ₹768-807 per share
  • Subscription Period: August 10-12
  • Scheduled Listing: August 17

The company’s rapid diagnosis technology, specifically for conditions like TB and COVID-19, has secured endorsement from the World Health Organization (WHO). This highlights the platform’s global recognition.

Future Investments

  • Establishing a new research and development facility.
  • Developing a Centre of Excellence via its wholly-owned subsidiary, Bigtec.
  • Upgrading existing office infrastructure.
  • Procuring plant, machinery, and equipment for manufacturing units in Goa and Visakhapatnam.

Backed by investors such as Temasek and Motilal Oswal, Molbio Diagnostics projects a Compound Annual Growth Rate (CAGR) of 31.5% in revenue between fiscal years 2024 and 2026. This financial outlook underlines its growth trajectory.

The IPO subscription window closes on August 12, with shares expected to list on August 17.

Home/business/Article